Investigating a key enzyme's role in diabetic retinopathy
Soluble guanylate cyclase in diabetic retinopathy
['FUNDING_R01'] · JOHNS HOPKINS UNIVERSITY · NIH-11037977
This study is looking at how a specific protein might help protect your eyes from damage caused by diabetes, with the hope of finding new treatments to prevent vision loss from diabetic retinopathy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11037977 on ClinicalTrials.gov |
What this research studies
This research focuses on diabetic retinopathy, a leading cause of blindness, by exploring the role of soluble guanylate cyclase (sGC) in the disease's progression. The study aims to identify how oxidative stress affects sGC and its potential as a therapeutic target. Using both laboratory and animal models, researchers will investigate the neuroprotective effects of sGC activators, which could lead to new treatment options for patients with diabetic retinopathy. The goal is to enhance understanding of the disease and develop strategies to prevent vision loss.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with diabetic retinopathy, particularly those in the early stages of the disease.
Not a fit: Patients with advanced diabetic retinopathy who have already lost significant vision may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent or slow the progression of diabetic retinopathy, potentially preserving vision for many patients.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting soluble guanylate cyclase in other conditions, indicating potential for success in this area.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DUH, ELIA J — JOHNS HOPKINS UNIVERSITY
- Study coordinator: DUH, ELIA J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: blood vessel disorder